← FDA DRUG APPROVALS

FDA ANDA · ANDA065204

CEFTRIAXONE SODIUM

Sponsor: SANDOZ INC

APPLICATION
ANDA065204
TYPE
ANDA
ORIGINAL APPROVAL
2005-05-03
LATEST ACTION
2022-01-13
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CEFTRIAXONEDiscontinued
CEFTRIAXONE SODIUM EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
CEFTRIAXONEDiscontinued
CEFTRIAXONE SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2022-01-13Labeling · Supplement 28 · standardAP
2020-09-11Labeling · Supplement 26 · standardAP
2016-03-05Labeling · Supplement 17 · standardAP
2016-03-05Labeling · Supplement 15 · standardAP
2016-03-05Labeling · Supplement 16 · standardAP
2011-07-13Labeling · Supplement 9AP
2010-07-31Labeling · Supplement 6AP
2009-01-14Labeling · Supplement 3AP
2005-05-03Original — Other Important Information from FDA ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →